Published in Am J Physiol Gastrointest Liver Physiol on March 03, 2005
Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut (2008) 1.56
Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis. PLoS Med (2012) 1.27
The liver-brain axis of alcohol-mediated neurodegeneration: role of toxic lipids. Int J Environ Res Public Health (2009) 1.00
Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters. Pflugers Arch (2013) 0.97
Phosphatidylinositol-3-kinase p110γ contributes to bile salt-induced apoptosis in primary rat hepatocytes and human hepatoma cells. J Hepatol (2010) 0.85
INTRACELLULAR SIGNALING BY BILE ACIDS. J Biosci (Rajshari) (2012) 0.78
Sulfasalazine reduces bile acid induced apoptosis in human hepatoma cells and perfused rat livers. Gut (2005) 0.78
p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol (2002) 3.80
Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology (2002) 2.64
CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology (2005) 2.45
Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology (2012) 2.39
Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology (2010) 2.18
Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology (2004) 2.02
Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis. Hepatology (2013) 2.02
Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology (2002) 1.98
BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology (2004) 1.88
Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol (2009) 1.87
Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol (2003) 1.85
Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol (2012) 1.84
Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology (2005) 1.84
Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis (2010) 1.79
Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology (2003) 1.79
Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology (2009) 1.72
High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol (2008) 1.72
A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am J Pathol (2007) 1.70
Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology (2009) 1.69
Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Am J Physiol Gastrointest Liver Physiol (2005) 1.64
Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol (2005) 1.62
Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol (2012) 1.58
Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol (2011) 1.57
Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics (2004) 1.56
Pregnancy in primary sclerosing cholangitis. Gut (2011) 1.55
24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology (2006) 1.54
Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice. Liver Int (2008) 1.52
Primary biliary cirrhosis. Semin Immunopathol (2009) 1.46
Oncosis represents the main type of cell death in mouse models of cholestasis. J Hepatol (2005) 1.46
Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet (2010) 1.43
Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics (2007) 1.43
Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. Liver Int (2014) 1.43
MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis (2007) 1.42
Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol (2003) 1.41
Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology (2013) 1.39
Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol (2006) 1.30
Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J Clin Gastroenterol (2005) 1.30
Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol (2012) 1.29
Mallory body--a disease-associated type of sequestosome. Hepatology (2002) 1.28
Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. Nat Clin Pract Gastroenterol Hepatol (2006) 1.27
Intrahepatic cholestasis of pregnancy. Orphanet J Rare Dis (2007) 1.27
Fxr(-/-) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. J Lipid Res (2005) 1.22
Focal nodular hyperplasia and hepatic adenoma: epidemiology and pathology. Dig Surg (2010) 1.22
Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis (2012) 1.21
Overlap syndromes among autoimmune liver diseases. World J Gastroenterol (2008) 1.21
Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis. Gastroenterology (2010) 1.17
Bile salts and cholestasis. Dig Liver Dis (2010) 1.16
Nucleosomal DNA fragments in autoimmune diseases. Ann N Y Acad Sci (2006) 1.16
The keratin cytoskeleton in liver diseases. J Pathol (2004) 1.15
Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology (2005) 1.15
Spontaneous cholecysto- and hepatolithiasis in Mdr2-/- mice: a model for low phospholipid-associated cholelithiasis. Hepatology (2004) 1.15
Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology (2014) 1.13
Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien Med Wochenschr (2008) 1.13
Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease. J Hepatol (2002) 1.11
A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology (2012) 1.11
Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output. Hepatology (2011) 1.11
Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int (2005) 1.10
Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis (2004) 1.09
Hepatotoxicity of NONI juice: report of two cases. World J Gastroenterol (2005) 1.09
Bile acid-induced apoptosis in hepatocytes is caspase-6-dependent. J Biol Chem (2008) 1.08
Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One (2010) 1.07
Antimitochondrial antibodies may be insufficiently specific to define primary biliary cirrhosis-like disease in mouse models. Hepatology (2013) 1.07
Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol (2006) 1.05
Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology (2011) 1.05
Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int (2007) 1.05
Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol (2011) 1.04
Bile acid-induced Mallory body formation in drug-primed mouse liver. Am J Pathol (2002) 1.03
In vitro production of Mallory bodies and intracellular hyaline bodies: the central role of sequestosome 1/p62. Hepatology (2007) 1.02
Genetic background effects of keratin 8 and 18 in a DDC-induced hepatotoxicity and Mallory-Denk body formation mouse model. Lab Invest (2012) 1.02
Testicular inflammation as a new manifestation of IgG4-associated disease. Urology (2013) 1.02
Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. J Hepatol (2012) 1.00
Mediators of pruritus during cholestasis. Curr Opin Gastroenterol (2011) 0.99
Immunoglobulin G4-associated cholangitis: one variant of immunoglobulin G4-related systemic disease. Digestion (2009) 0.97
Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver. Am J Physiol Gastrointest Liver Physiol (2005) 0.96
Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. J Hepatol (2005) 0.95
Pathogenesis and treatment of pruritus in cholestasis. Drugs (2008) 0.93
Interaction of stress proteins with misfolded keratins. Eur J Cell Biol (2005) 0.93
Will we ever model PSC? - "it's hard to be a PSC model!". Clin Res Hepatol Gastroenterol (2011) 0.93
Intrahepatic cholestasis of pregnancy--a heterogeneous group of pregnancy-related disorders? Hepatology (2006) 0.92
IgG4-associated cholangitis: a comprehensive review. Clin Rev Allergy Immunol (2015) 0.91
Budesonide in previously untreated autoimmune hepatitis. Liver Int (2005) 0.91
Exposure to occupational antigens might predispose to IgG4-related disease. Hepatology (2014) 0.91
Tauroursodeoxycholic acid reduces bile acid-induced apoptosis by modulation of AP-1. Biochem Biophys Res Commun (2007) 0.91
Cytokeratins as targets for bile acid-induced toxicity. Am J Pathol (2002) 0.91
Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology (2003) 0.90
Expression of the hepatocyte canalicular multidrug resistance protein (MRP2) in primary biliary cirrhosis. Hepatol Res (2002) 0.90
Ursodeoxycholic acid treatment of vanishing bile duct syndromes. World J Gastroenterol (2006) 0.90